Lilly Stock Heading $1,000? What Investors Should Know
Investors are watching Eli Lilly as GLP-1 drugs like Mounjaro and Zepbound power growth. This article breaks down the...
Explore ways to make money instantly at no cost. These options can help you generate income quickly and efficiently.
21,459 articlesInvestors are watching Eli Lilly as GLP-1 drugs like Mounjaro and Zepbound power growth. This article breaks down the...
A big fund move can shift sentiment and pricing. This article breaks down the implications of baillie gifford dumps 2...
A new Gartner study shows that cutting jobs after piloting AI isn’t reliably boosting returns for many large firms. T...
Learn how to read a 2026 earnings call transcript with a practical, real-world lens. We break down a hypothetical GHI...
Pfizer faced big headwinds after its Covid-era peak, but a longer horizon could open doors for outsized returns. Here...
Canaccord Genuity raised its price target on C3.ai to $8 from $7 after Tom Siebel returned as CEO, amid preliminary Q...
When Valens Semiconductor released its first-quarter results, investors pushed valuations higher. This article breaks...
Explore Innoviz's path in 2026 with a deep dive into Q1 results, margins, backlog, and strategic bets. This analysis ...
Global markets sold off after leaders offered little concrete trade progress. Investors warn that day one of talks ma...
The 2027 COLA estimate has jumped to 3.2% from 1.2%, aided by March inflation and higher energy prices. Retirees face...
Pershing Square signals a bold bet by leaning into Microsoft as the AI and cloud wave reshapes enterprise tech. The m...
In a choppy 2026 market, a momentum-focused ETF is gaining attention for its track record of catching leaders while a...